恒生创新药ETF（159316）规模屡创新高，创业药产业再迎政策红利

Group 1 - The National Healthcare Security Administration has announced the preliminary results for the 2025 "Medical Insurance Directory + Commercial Insurance Innovative Drug Directory," with 534 generic names approved for medical insurance and 121 for commercial insurance, marking the beginning of a dual-track payment system for innovative drugs [1] - Recent market sentiment for innovative drugs continues to rise, with significant potential for further growth in the sector. There have been ongoing developments in outbound licensing transactions, indicating that many high-quality domestic innovative drugs may have opportunities for international expansion [1] - The adjustment of the medical insurance directory and the advancement of commercial insurance policies in the second half of the year are expected to serve as important catalysts for the industry [1] Group 2 - The new compilation scheme for the Hang Seng Hong Kong Stock Connect Innovative Drug Index has taken effect, focusing exclusively on innovative drug companies and achieving a "100% purity" in the ETF tracking index [1] - Backtesting shows that since the adjustment, the index has demonstrated higher annualized returns and Sharpe ratios since its launch on July 10, 2023 [1] - The Hang Seng Innovative Drug ETF (159316) is the only product tracking this index, having attracted significant investment with its latest scale exceeding 1.2 billion yuan, reaching a historical high, thus enabling investors to share in the industry's development dividends [1]